v3.25.2
Marketable Securities
6 Months Ended 12 Months Ended
Jun. 30, 2025
Dec. 31, 2024
IKENA ONCOLOGY INC    
Marketable Securities
4. Marketable Securities
The following tables summarize the Company’s marketable securities (in thousands):
 
    
June 30, 2025
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
    
Fair
Value
 
Corporate debt securities
     37,287        70        (5      37,352  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 37,287      $ 70      $ (5    $ 37,352  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2024
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
    
Fair
Value
 
U.S. treasury securities
   $ 26,985      $ 19      $ —       $ 27,004  
Corporate debt securities
     57,940        84        (35      57,989  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 84,925      $ 103      $ (35    $ 84,993  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
During the three and six months ended June 30, 2025, the Company sold marketable securities with a fair value of $37.4 million for proceeds of approximately the same amount and a minimal amount of realized gains.
In accordance with the Company’s investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or
non-credit-related
factors, the financial condition and near-term prospects of the issuer, and the Company’s intent and ability to hold the investment to allow for an anticipated recovery in fair value. As of June 30, 2025 and December 31, 2024, there were no allowances for credit losses recorded.
The Company classifies its investments in marketable securities as
available-for-sale
and as current assets as they represent the investment of funds available for current operations. The following table summarizes the fair value of the Company’s
available-for-sale
securities by contractual maturity (in thousands):
 
    
June 30, 2025
 
Due in one year or less
   $ 21,706  
Due after one year through two years
     15,646  
  
 
 
 
Total
   $ 37,352  
  
 
 
 
4. MARKETABLE SECURITIES
The following tables summarize the Company’s marketable securities (in
thousands
):
 
    
December 31, 2024
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
    
Fair
Value
 
U.S. treasury securities
   $ 26,985      $ 19      $ —       $ 27,004  
Corporate debt securities
     57,940        84        (35      57,989  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 84,925      $ 103      $ (35    $ 84,993  
  
 
 
    
 
 
    
 
 
    
 
 
 
 
    
December 31, 2023
 
    
Amortized
Cost
    
Gross
Unrealized
Gains
    
Gross
Unrealized
Losses
    
Fair
Value
 
Corporate debt securities
   $ 55,624      $ 27      $ (80    $ 55,571  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 55,624      $ 27      $ (80    $ 55,571  
  
 
 
    
 
 
    
 
 
    
 
 
 
In accordance with the Company’s investment policy, it places investments in investment grade securities with high credit quality issuers, and generally limits the amount of credit exposure to any one issuer. The Company evaluates securities for impairment at the end of each reporting period. Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or
non-credit-related
 
factors, the financial condition and near-term prospects of the issuer, and the Company’s intent and ability to hold the investment to allow for an anticipated recovery in fair value. As of December 31, 2024 and 2023, there were no allowances for credit losses recorded.
The Company classifies its investments in marketable securities as
available-for-sale
and as current assets as they represent the investment of funds available for current operations. The following table summarizes the fair value of the Company’s
available-for-sale
securities by contractual maturity (in thousands):
 
    
December 31,
2024
 
Due in one year or less
   $ 70,636  
Due after one year through two years
     14,357  
  
 
 
 
Total
   $ 84,993